{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/uveitis/management/management/","result":{"pageContext":{"chapter":{"id":"4979504e-a9bf-5af0-85e3-9dc3768f890c","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field e14e06b1-e396-429c-91df-9ea45d4961f5 --><h2>Scenario: Management</h2><!-- end field e14e06b1-e396-429c-91df-9ea45d4961f5 -->","summary":"Covers the primary care management of people with suspected uveitis.","htmlStringContent":"<!-- begin item ad80e96d-91a6-4833-8002-950f4983dd77 --><!-- begin field 399b0ba0-0b8b-4ba7-ab98-acbc015b366e --><p>From birth onwards.</p><!-- end field 399b0ba0-0b8b-4ba7-ab98-acbc015b366e --><!-- end item ad80e96d-91a6-4833-8002-950f4983dd77 -->","topic":{"id":"4e7f8958-fe40-50b7-8ec8-2b083c8f6d9f","topicId":"5ed561ca-031e-4b81-b7b9-983a4596f57d","topicName":"Uveitis","slug":"uveitis","lastRevised":"Last revised in November 2019","chapters":[{"id":"c1e5701f-4cf7-5b69-b095-728c2e750a2e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b652ef07-4a12-5bb0-a4b9-c1094cf2e1d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2207db21-1f9e-5e39-93b5-7fc6a06aa966","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1a49d275-1794-5c25-90df-8f0530f899ec","slug":"changes","fullItemName":"Changes"},{"id":"da048924-1bce-5637-a71a-d7ff26956aa2","slug":"update","fullItemName":"Update"}]},{"id":"db656a2f-7785-5776-ae8b-48cdfd7756f8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"47bb0526-e4db-56a3-a194-a706b3b3140c","slug":"goals","fullItemName":"Goals"},{"id":"1f8904c0-9580-5baa-9124-abb6169557cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e4f30ebb-13db-5f25-8c8c-2922bf0324c2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c38307ad-dc15-5b55-9372-253747056a05","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a5a31d4b-de2a-54ff-81c0-6c61354951a9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3f8284ba-ca4f-5550-891b-a8bb66ae561a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d254b372-3c06-50bd-a365-07955b3fb044","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"40e37db0-0ff9-5e4e-a5d9-a3961f2ae4ef","slug":"definition","fullItemName":"Definition"},{"id":"a22de773-ef70-5bde-b110-c2f1262f2190","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"3315c723-dddf-57fc-84b3-dc09ea047f7b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c59a26aa-291d-58eb-ad48-cb4dded2b859","slug":"complications","fullItemName":"Complications"},{"id":"36d5a1d4-9b5d-5c62-81e5-0c43edd11e00","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"0cfa2942-a69a-5096-8ae9-f7861442f3f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e5becea0-9248-5f2a-83e3-24b1e3d4ce6b","slug":"assessment","fullItemName":"Assessment"},{"id":"a9640992-20d3-5ba2-bdd7-ec93af987f32","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4047e2b5-894c-544b-b383-bff07703393f","fullItemName":"Management","slug":"management","subChapters":[{"id":"4979504e-a9bf-5af0-85e3-9dc3768f890c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"df7eae5d-b45a-51a6-a36f-a765d5316352","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ce1f7b0f-39da-5d16-bebb-8843f476896e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4c41e5af-5272-5e11-9e17-c8316e740974","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"552ccc38-bb09-5038-bc2c-1c084a3b1ee9","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"06fa45da-6a9c-586f-b111-cfdb08482ec5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5c6898e0-edbd-5964-adb0-5002730568b9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2e9caef7-3fad-5071-a98a-9facdf639f41","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1d32651a-229f-569e-914a-25bba4c7f533","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4047e2b5-894c-544b-b383-bff07703393f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"038b1c94-59b0-52d1-a602-d52149c2e66e","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field f0c30f3f-5f1e-4c5a-bcea-1560c891c650 --><h3>How should I manage someone with suspected uveitis?</h3><!-- end field f0c30f3f-5f1e-4c5a-bcea-1560c891c650 -->","summary":null,"htmlStringContent":"<!-- begin item 3c520c93-bb54-4140-90a6-04dfbfd23fd9 --><!-- begin field f0a6b773-e263-444c-b2f5-4303867f5d58 --><ul><li><strong>Refer people with severe eye pain and a significant reduction in vision immediately for same-day assessment by an ophthalmologist. </strong></li><li><strong>Refer people with suspected uveitis (new presentations, and recurrent) for assessment within 24 hours by an ophthalmologist. </strong><ul><li>Urgent referral is required to confirm the diagnosis with a slit lamp examination with dilated pupils and measurement of intraocular pressure.</li></ul></li><li><strong>Uveitis should be managed by an ophthalmologist; </strong><a class=\"topic-reference internal-reference\" href=\"/topics/uveitis/management/management/#secondary-care-treatments\">secondary care treatment</a> will depend on the underlying cause of the uveitis.</li><li><strong><em>Do not </em>initiate treatment for uveitis in primary care, unless asked to do so by an ophthalmologist. </strong></li></ul><!-- end field f0a6b773-e263-444c-b2f5-4303867f5d58 --><!-- end item 3c520c93-bb54-4140-90a6-04dfbfd23fd9 -->","subChapters":[{"id":"4a99d377-cee9-5c5a-98b0-71fcf5e16e6e","slug":"secondary-care-treatments","fullItemName":"Secondary care treatments","depth":4,"htmlHeader":"<!-- begin field 4172cf24-8942-4f2c-b970-a0efa945a924 --><h4>Secondary care treatments</h4><!-- end field 4172cf24-8942-4f2c-b970-a0efa945a924 -->","summary":null,"htmlStringContent":"<!-- begin item 23e9f4f3-041e-4151-a445-d1fdae3094d2 --><!-- begin field eb0b50bb-cabf-4e8d-b28c-474b62d17f93 --><ul><li>Treatment of uveitis depends on the cause, location and severity of disease, and is aimed at controlling ocular disease and the underlying systemic condition (if present).  </li><li><strong>Non-infectious uveitis</strong><ul><li>Corticosteroids are used to reduce inflammation and prevent adhesions in the eye. They may be given topically, orally, intravenously, intramuscularly, or by periocular or intraocular injection or implant. Corticosteroids are tapered slowly (over weeks) because withdrawing them too quickly may lead to rebound inflammation.<ul><li>Corticosteroids achieve immediate control of inflammation rapidly and effectively, but long-term use is associated with numerous adverse effects. </li></ul></li><li>A cycloplegic-mydriatic drug (for example cyclopentolate 1% or atropine 1%) may also be given to paralyse the ciliary body. This relieves pain and prevents adhesions between the iris and lens.</li><li>People with severe or chronic uveitis may also be given systemic immunosuppressive drugs (for example, methotrexate or mycophenolate), tumour necrosis factor (TNF) inhibitors (for example, adalimumab), laser phototherapy, cryotherapy, or have the vitreous removed surgically (vitrectomy).</li></ul></li><li><strong>Infectious uveitis</strong><ul><li>Infectious uveitis (bacterial, viral, fungal, or parasitic) is treated with an appropriate antimicrobial drug as well as corticosteroids and cycloplegics.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Gupta, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Guly, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Yanoff, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">MSD, 2019</a>]</p><!-- end field eb0b50bb-cabf-4e8d-b28c-474b62d17f93 --><!-- end item 23e9f4f3-041e-4151-a445-d1fdae3094d2 -->","subChapters":[]},{"id":"7405abe0-a7a3-59de-b5a0-fd0fdd74f8e3","slug":"basis-for-recommendation-7b5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field eb271864-49b0-457d-893a-93e2886ba4d1 --><h4>Basis for recommendation</h4><!-- end field eb271864-49b0-457d-893a-93e2886ba4d1 -->","summary":null,"htmlStringContent":"<!-- begin item 7b5e6fdd-9042-4629-91d2-92d0832ff5d1 --><!-- begin field 896bba13-4a57-4d93-8716-1083dd56eefa --><p>These recommendations are based on the College of Optometrists guidelines <em>Uveitis (anterior)</em> and <em>Urgency of referrals </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">The College of Optometrists, 2019b</a>], expert opinion in narrative reviews <em>Investigation and management of uveitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Guly, 2010</a>], <em>Evaluation of the painful eye</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Pflipsen, 2016</a>], <em>Assessing the painful, uninflamed eye in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Kuffova, 2015</a>], <em>Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Gupta, 2006</a>], <em>Diagnosis and treatment of anterior uveitis: optometric management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Harthan, 2016</a>], and a medical textbook <em>Ophthalmology </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Yanoff, 2013</a>]. </p><h5>Referral</h5><ul><li>The recommendations regarding referral are largely based on expert opinion in a narrative review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Guly, 2010</a>], and a medical textbook <em>Ophthalmology </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Yanoff, 2013</a>].<ul><li>Uveitis cannot be diagnosed without slit-lamp examination which may show inflammatory cells that may aggregate to form 'snowballs'.</li><li>Uveitis usually resolves quickly with treatment; however, if it is not treated or is inadequately treated, it may result in profound and irreversible vision loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Gupta, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">MSD, 2019</a>]. </li></ul></li><li>People with eye pain in an uninflamed eye should be referred to secondary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Kuffova, 2015</a>]: <ul><li>Immediately (within hours)—if there is evidence of acute onset sight loss (more than two lines on Snellen chart), or suspicion of giant cell arteritis, or raised intracranial pressure.</li><li>Soon (within days)— if there is a perceived risk of sight loss based on the suspected diagnosis (such as chronic glaucoma or uveitis).</li></ul></li><li>Eye pain with vision loss requires immediate ophthalmology referral [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Pflipsen, 2016</a>].  </li><li>Emergency referral (same day) to an ophthalmologist (with no intervention) is required for people with a significant reduction in vision, severe pain, or significantly raised intraocular pressure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">The College of Optometrists, 2019a</a>]. </li><li>Emergency referral (within 24 hours) is required for people with uveitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">The College of Optometrists, 2019b</a>]. </li></ul><h5>Treatment </h5><ul><li>CKS recommends that people with suspected uveitis in primary care should be referred without treatment because:<ul><li>The diagnosis must be confirmed by slit-lamp examination (not normally readily available in primary care).</li><li>Viral infections are the most common infectious underlying cause of anterior uveitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Harthan, 2016</a>]. </li><li>If the person has herpes simplex virus infection, corticosteroids can transform a simple herpetic dendritic ulcer into an extensive amoeboid ulcer involving all layers of the cornea, with resultant corneal scarring and visual impairment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Frith et al, 2001</a>].</li><li>Topical steroids should be used with care in eyes with herpes simplex uveitis because of the risk of exacerbation of corneal epithelial disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Guly, 2010</a>].</li></ul></li></ul><!-- end field 896bba13-4a57-4d93-8716-1083dd56eefa --><!-- end item 7b5e6fdd-9042-4629-91d2-92d0832ff5d1 -->","subChapters":[]}]},{"id":"f6fbb424-a666-5d6f-ba4d-f65719a44589","slug":"follow-up","fullItemName":"Follow-up","depth":3,"htmlHeader":"<!-- begin field 982d5a88-0531-4594-a426-ab0900d5b88e --><h3>How should I follow-up someone diagnosed with uveitis? </h3><!-- end field 982d5a88-0531-4594-a426-ab0900d5b88e -->","summary":null,"htmlStringContent":"<!-- begin item d8a049ea-fd5c-456e-89c8-ab0900d5b83d --><!-- begin field 38ed560a-7ac9-45fe-b69b-ab0900d5b88e --><ul><li><strong>Secondary care follow-up of uveitis includes monitoring for:</strong><ul><li>Treatment efficacy — if the person responds well to treatment the dose of corticosteroid may be reduced, then tapered over 6 weeks. </li><li>Adverse effects, for example: <ul><li>Measuring intraocular pressure to assess for glaucoma as a result of corticosteroid use. </li><li>Full blood count to check for neutropenia caused by immunosuppressants. </li></ul></li><li>Uveitis complications — for example, deterioration in vision.</li></ul></li><li><strong>Primary healthcare professionals may be asked to monitor:</strong><ul><li>For adverse effects of long-term oral corticosteroids (continuous or repeated courses).<ul><li>For more information see the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li><li>The use of disease-modifying antirheumatic drugs (DMARDs) or immunosuppressants, depending on locally-agreed shared care guidelines. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a>.</li><li>That people receiving repeat prescriptions of topical corticosteroids are under the care of an ophthalmologist (to monitor for corticosteroid-induced glaucoma).</li></ul></li></ul><!-- end field 38ed560a-7ac9-45fe-b69b-ab0900d5b88e --><!-- end item d8a049ea-fd5c-456e-89c8-ab0900d5b83d -->","subChapters":[{"id":"4ed40ebe-0b27-5436-a843-47b9a5c7e1de","slug":"basis-for-recommendation-689","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 02835aed-d347-4355-bc76-ab0900d5b896 --><h4>Basis for recommendation</h4><!-- end field 02835aed-d347-4355-bc76-ab0900d5b896 -->","summary":null,"htmlStringContent":"<!-- begin item 6894e028-18cb-48a3-9864-ab0900d5b896 --><!-- begin field 9065bc86-31b5-4faa-a537-ab0900d5b896 --><p>These recommendations are based on the British Medical Journal (BMJ) Best Practice guide <em>Uveitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">BMJ, 2018</a>], the College of Optometrists guideline <em>Uveitis (anterior)</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">The College of Optometrists, 2019b</a>], expert opinion in narrative reviews <em>Investigation and management of uveitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Guly, 2010</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/uveitis/references/\">Joint Formulary Committee, 2019</a>]. </p><!-- end field 9065bc86-31b5-4faa-a537-ab0900d5b896 --><!-- end item 6894e028-18cb-48a3-9864-ab0900d5b896 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}